About you
What is your name?
Full name
(Required)
Ryan Courtney
Which best describes your response? Please read the definition of "on behalf of an organisation" at the top of this page before responding.
Please select one item
(Required)
Radio button:
Ticked
I am responding as an individual
Radio button:
Unticked
I am responding on behalf of an organisation / institution
Individual
Which best describes you?
Please select one item
Radio button:
Unticked
Consumer / patient
Radio button:
Unticked
Registered healthcare professional
Radio button:
Ticked
Professional researcher
Radio button:
Unticked
None of the above / I am responding out of personal interest
Consultation Page
Please indicate your level of support for the interim decision with respect to CYTISINE
Please select one item
(Required)
Radio button:
Ticked
Support interim decision
Radio button:
Unticked
Partially support interim decision
Radio button:
Unticked
Do not support interim decision
Radio button:
Unticked
No comment
Short-text response
Access and scheduling of cytisine as S3 is appropriate and it is possible as the Scheduling Committee points out that as local data accumulates that it is possible that cytisine may be scheduled differently in the future and possibly over the counter.
I do however have some significant reservations on not allowing advertising direct to smokers/ patients. Cytisine is a product that has been available in some countries for several decades. The safety and adverse event profile is widely understood and the risk associated with continued smoking for smokers far outweighs any possible downsides to advertising. Our recent trial published in JAMA illustrated cytisine's superior adverse event profile compared to varenicline.
It is imperative smokers are aware of cytisine as a treatment option and I think an advertising ban would be problematic for the public's awareness and greatest possible update of an extremely effective and tolerable medicine for smoking cessation.
I do however have some significant reservations on not allowing advertising direct to smokers/ patients. Cytisine is a product that has been available in some countries for several decades. The safety and adverse event profile is widely understood and the risk associated with continued smoking for smokers far outweighs any possible downsides to advertising. Our recent trial published in JAMA illustrated cytisine's superior adverse event profile compared to varenicline.
It is imperative smokers are aware of cytisine as a treatment option and I think an advertising ban would be problematic for the public's awareness and greatest possible update of an extremely effective and tolerable medicine for smoking cessation.
Please indicate your level of support for the interim decision with respect to DEXTROMETHORPHAN
Please select one item
(Required)
Radio button:
Unticked
Support interim decision
Radio button:
Unticked
Partially support interim decision
Radio button:
Unticked
Do not support interim decision
Radio button:
Ticked
No comment